Healthcare stocks have quietly moved into focus after the June US jobs report showed only 57,000 new roles and softer hiring across most cyclical sectors. With much of June’s job growth coming from healthcare and investors rotating out of semiconductor and AI stocks, this corner of the market is drawing fresh attention from those looking for resilience when other areas look more uncertain. This article looks at how that weak jobs print and sector rotation could shape sentiment toward healthcare, and highlights 3 stocks from our Healthcare Sector Stocks screener that appear positively exposed to the current news backdrop.

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics is a US biopharmaceutical company focused on drugs that modulate cortisol to treat severe endocrine, oncologic, metabolic, and neurologic disorders, including Cushing’s syndrome and platinum resistant ovarian cancer.

Operations: Corcept Therapeutics generates all of its US$769.1 million in annual revenue from the discovery, development and commercialization of pharmaceutical products in the United States.

Market Cap: US$9.50b

Corcept Therapeutics stands out in healthcare because it already sells Korlym for Cushing’s syndrome while advancing a pipeline of selective cortisol modulators for broader potential uses, from metabolic disease to ovarian cancer. Recent NDA resubmissions for relacorilant and ROSELLA trial data indicate that Corcept may reduce its dependence on Korlym over time, although legal disputes, pricing pressure and a recent swing to a net loss show that execution involves meaningful risk. Analyst forecasts for earnings and revenue, combined with an experienced management team and active share buybacks, give investors reasons to monitor how upcoming FDA decisions and trial readouts could influence the company’s transition from single product reliance to a more diversified endocrine and oncology platform.

Corcept Therapeutics is shifting from a single drug story to a broader cortisol platform, but the real question is what that pivot means for future earnings. Get the full picture in the analyst forecasts for Corcept Therapeutics

Insulet (PODD)

Overview: Insulet develops and sells the Omnipod family of tubeless insulin pumps, including the Omnipod 5 automated insulin delivery system. This system pairs with continuous glucose monitors to help people with insulin dependent diabetes manage blood sugar with fewer manual injections. The company also supplies its pod technology for Amgen’s Neulasta Onpro kit, extending its reach into oncology support care.

Operations: Insulet generates about US$2.9b in annual revenue from drug delivery systems, with roughly US$2.1b from the United States and US$844.9m from international markets.

Market Cap: US$11.1b

Insulet operates in essential, recurring healthcare demand that can attract investor attention when cyclical jobs data weakens. Its Omnipod 5 platform and next generation closed loop systems are positioned within diabetes care as more patients and payers use wearable, app connected devices. Revenue growth has been strong, analysts expect earnings and margins to improve further, and recent clinical and regulatory milestones around Omnipod 6 and fully closed loop systems for type 2 diabetes point to a larger addressable market. The company’s reliance on a single product family and recent recalls indicate that execution and product quality remain critical factors for the investment case.

Insulet’s recurring diabetes revenue story is only half the picture; the real tension sits in how growth, profitability and product risks stack up in the analyst forecasts for Insulet

Gilead Sciences (GILD)

Overview: Gilead Sciences is a global biopharmaceutical company that develops and sells treatments for HIV, viral hepatitis, COVID-19, serious fungal infections and several cancers, including CAR T-cell therapies and the breast cancer drug Trodelvy.

Operations: Gilead generates about US$29.7b in annual revenue from the discovery, development and commercialization of medicines, with sales spread across the United States, Europe and the rest of the world.

Market Cap: US$163.0b

Gilead Sciences provides exposure to large, long duration markets such as HIV and oncology, backed by products including Biktarvy, Yeztugo and Trodelvy that are already in use and gaining new approvals across the US and Europe. Earnings growth, a 31% net margin, strong cash generation and a 2.5% dividend are on the positive side. However, a heavy tilt toward HIV therapies, high debt and rising R&D and pricing pressures add risk. With healthcare taking a bigger share of job growth while more cyclical areas cool, it is worth understanding how Gilead’s expanding pipeline, capital returns and funding profile fit together before deciding where it belongs in a portfolio.

Gilead Sciences appears to be a heavyweight, where HIV cash flows and oncology ambitions might be masking an underappreciated twist in the story. Get the context in the analysis report for Gilead Sciences

The three healthcare stocks covered here are just a starting point, and the full Healthcare Sector Stocks screener surfaces 37 more companies with equally compelling healthcare narratives that could fit different risk and income preferences. Use Simply Wall St to identify and analyze the specific catalysts, financial profiles and business stories that matter most so you can focus on the healthcare opportunities that best match your highest conviction ideas.

Take Control of Your Investment Journey

If Corcept Therapeutics or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Healthcare?

Some of the most interesting stock stories can move fast, with momentum building or dropping before the crowd catches on. Scan these fresh ideas while it still matters and consider your options promptly.

• Spot companies where steady fundamentals back the story and use the list of solid balance sheet and fundamentals (46 results) to see which businesses still look under the radar for now.
• Explore early momentum in companies connected to AI demand across chips, data centers and software by browsing the curated 52 AI infrastructure stocks before they attract wider attention.
• Hunt for income opportunities that might hold up when growth feels uncertain by reviewing the curated 7 dividend fortresses and see which payouts still look supported by real cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.